Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Sales and Divestitures: 2024-2025

Historic Gains from Sales and Divestitures for Insight Molecular Diagnostics (IMDX) over the last 1 years, with Sep 2025 value amounting to $20,000.

  • Insight Molecular Diagnostics' Gains from Sales and Divestitures rose 400.00% to $20,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $20,000, marking a year-over-year increase of 400.00%. This contributed to the annual value of $17,000 for FY2024, which is N/A change from last year.
  • Insight Molecular Diagnostics' Gains from Sales and Divestitures amounted to $20,000 in Q3 2025, which was up 11.11% from $18,000 recorded in Q2 2025.
  • Insight Molecular Diagnostics' Gains from Sales and Divestitures' 5-year high stood at $20,000 during Q3 2025, with a 5-year trough of $4,000 in Q2 2024.
  • For the 2-year period, Insight Molecular Diagnostics' Gains from Sales and Divestitures averaged around $12,600, with its median value being $17,000 (2024).
  • Data for Insight Molecular Diagnostics' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 400.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Insight Molecular Diagnostics' Gains from Sales and Divestitures stood at $17,000 in 2024, then surged by 400.00% to $20,000 in 2025.
  • Its last three reported values are $20,000 in Q3 2025, $18,000 for Q2 2025, and $17,000 during Q4 2024.